Protocols - Page 4 of 6 - PeptideDosing.ca

20 Feb

Oxytocin acetate (10 mg vial) — Evidence profile

Oxytocin has different clinical and experimental uses. Evidence for one route or endpoint should remain tied to that question. This profile distinguishes the labelled product, study findings and evidence limits.

20 Feb

Single Peptides

NAD (1000 mg vial) — Evidence profile

NAD+ is a coenzyme involved in cellular metabolism. Measuring its fate after infusion is a different question from demonstrating a clinical benefit. This profile distinguishes the labelled product, study findings and evidence limits.

20 Feb

Single Peptides

Ovagen (20 mg Vial) — Evidence profile

The relevant evidence reviewed here concerns the EDL tripeptide in experimental cell cultures. This profile distinguishes the labelled product, study findings and evidence limits.

20 Feb

Single Peptides

MOTS-C (10 mg Vial) — Evidence profile

MOTS-c research connects mitochondrial signaling with metabolism and exercise. Published physiological observations and preclinical findings should be read separately from a registered human intervention trial whose results are not posted. This profile distinguishes the labelled product, study findings and evidence limits.

19 Feb

Single Peptides

Melanotan II (10 mg Vial) — Evidence profile

Melanotan II research includes a very small human pilot, while subsequent clinical reports document adverse events after internet-purchased material. This profile distinguishes the labelled product, study findings and evidence limits.

19 Feb

Single Peptides

Livagen (20 mg Vial) — Evidence profile

Livagen studies reviewed here concern experimental digestive-enzyme measurements and liver tissue cultures. This profile distinguishes the labelled product, study findings and evidence limits.

19 Feb

Single Peptides

LL-37 (5 mg Vial) — Evidence profile

Human LL-37 studies reviewed here evaluate local treatment of specific wounds. Their findings are mixed and should remain tied to those settings. This profile distinguishes the labelled product, study findings and evidence limits.

19 Feb

Single Peptides

KPV (10 mg Vial) — Evidence profile

KPV is a short peptide investigated in cellular and animal models of inflammatory signaling. This profile distinguishes the labelled product, study findings and evidence limits.

19 Feb

Single Peptides

Kisspeptin (10 mg Vial) — Evidence profile

Kisspeptin research includes short controlled studies in people with low sexual desire. The peptide form used in those studies is essential context. This profile distinguishes the labelled product, study findings and evidence limits.

19 Feb

Single Peptides

IGF-1 LR3 (1 mg Vial) — Evidence profile

IGF-1 LR3 is an analogue whose evidence must remain distinct from native IGF-1 and manufactured medicinal products. This profile distinguishes the labelled product, study findings and evidence limits.